

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 15 (2005) 41-45

Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist

Jun Chiba,^{a,*} Nobuo Machinaga,^a Tohru Takashi,^b Akio Ejima,^a Gensuke Takayama,^b Mika Yokoyama,^b Atsushi Nakayama,^a John J. Baldwin,^c Edward McDonald,^c Kurt W. Saionz,^c Robert Swanson,^c Zahid Hussain^c and Angela Wong^c

^aMedicinal Chemistry Research Laboratory, Daiichi Pharmaceutical, Co., Ltd, 16-13, Kitakasai 1-chome, Edogawa-ku, Tokyo 134-8630, Japan

^bNew Product Research Laboratories III, Daiichi Pharmaceutical, Co., Ltd, 16-13, Kitakasai 1-chome, Edogawa-ku, Tokyo 134-8630, Japan

^cPharmacopeia Drug Discovery, Inc., Princeton, NJ 08543-5350, USA

Received 18 August 2004; revised 12 October 2004; accepted 13 October 2004 Available online 2 November 2004

Abstract—An investigation into the structure–activity relationship of a lead compound, prolyl-5-aminopentanoic acid 4, led to the identification of a novel series of 4-piperidinylacetic acid, 1-piperazinylacetic acid, and 4-aminobenzoic acid derivatives as potent VLA-4 antagonists with low nanomolar IC₅₀ values. A representative compound morpholinyl-4-piperidinylacetic acid derivative (**13d**: IC₅₀ = 4.4 nM) showed efficacy in the *Ascaris*-antigen sensitized murine airway inflammation model by oral administration. © 2004 Elsevier Ltd. All rights reserved.

VLA-4 (very late antigen 4; $\alpha_4\beta_1$ integrin; CD49d/CD29) is a key cell receptor expressed on most leukocytes.¹ The natural ligands include VCAM-1 (vascular cell adhesion molecule-1) expressed on cytokine-stimulated endothelial cells and the alternatively spliced connecting segment-1 (CS-1) domain of fibronectin (FN) on the extracellular matrix.^{2,3} Recently, it has been reported that junctional adhesion molecule 2 (JAM2) on endothelial cells also interacts with VLA-4.⁴ Through the VLA-4/ligands interaction, VLA-4 plays an important role in the process of adhesion, migration, and activation of inflammatory leukocytes at sites of inflammation. It has been shown that anti-VLA-4 antibodies or VLA-4 antagonists⁵ inhibit leukocyte infiltration to extravascular tissue and prevent tissue damage in inflammatory disease models of asthma,⁶ multiple scle-rosis (MS),⁷ rheumatoid arthritis (RA),⁸ and inflammatory bowel disease (IBD).⁹ In addition, a humanized monoclonal *anti*- α_4 antibody (natalizumab,¹⁰ Elan Pharmaceuticals Inc.) has revealed efficacies for MS and

Crohn's disease in phase II clinical trials. Accordingly, orally active small molecule VLA-4 antagonists should represent an attractive target to enhance the therapeutic benefit.

It has been known that VLA-4 recognizes the sequences Ile-Asp-Ser (IDS) in VCAM and Leu-Asp-Val (LDV) in FN. Therefore, VLA-4 antagonists based on the LDV sequence have been extensively explored by a number of research groups.⁵ Among them, LDV mimics incorporated with the 4-(phenylureido)phenylacetyl moiety (diphenylurea portion, Fig. 1) at the N-terminus of the sequence have been reported to show efficacy in animal models, and some representatives such as Bio-1211 $(1)^{11}$ (Merck/Biogen, Fig. 1) and IVL-745 (2)¹² (Aventis, Fig. 1) have advanced into clinical trials as anti-asthmatic agents administered as inhalants. These compounds have poor pharmacokinetic profiles, however, such as low oral availability and high plasma clearance because of their residual peptidic character.⁵ Therefore, in our efforts to obtain an orally available VLA-4 antagonists, we identified a proline derivative, PS181895 (3, Fig. 2), with an IC_{50} value of 4.7 nM in the VLA-4/VCAM-1 binding assay. In addition, it was found that the 3-methylbutylaminocarbonyl group in 3 could be removed

Keywords: VLA-4; Integrin; Asthma.

^{*}Corresponding author. Tel.: +81 3 3680 0151; fax: +81 3 5696 8609; e-mail: chiba2mk@daiichipharm.co.jp

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter @ 2004 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2004.10.041



Figure 1. The structures of Bio-1211 and IVL-745.





Figure 2. The structures of identified lead compounds.

without significant loss of the activity, **PS969819** (4, Fig. 2) showed an IC₅₀ value of 7.1 nM. At this point, we considered that this simplified prolyl-5-aminopentanoic acid moiety should be useful as an LDV mimic structure for further optimization. This result led us to select the compound (4) as a lead compound for studies toward obtaining a new series of VLA-4 antagonists to show the more potent activity. Compound 4 can be divided into three portions (**a**–**c**) from its structural features (Fig. 2). To explore the structure–activity relationship (SAR), we focused several modifications on the **b** and **c** portions.

We report herein the identification of a novel series of 4-piperidinylacetic acid, 1-piperazinylacetic acid, and 4-aminobenzoic acid derivatives as potent VLA-4 antagonists and present the results of evaluating representative compounds in the murine asthma model.

Preparation of new compounds was carried out through route A or B in Scheme 1 by coupling three portions $\mathbf{a-c}$, which were easily prepared from commercially available compounds. In route A, **5** (portion a) was condensed with **6** (P = H, R = *tert*-Bu, portion **b**) by the standard amide bond-forming method (EDC and HOBt) followed by deprotection of the *tert*-butyl ester group with TFA to give **9**. Subsequent coupling with **7** and hydrolysis under basic condition provided **4**, **12a–f**, and **13a**. When portion **c** was methyl 4-aminobenzoate, the condensation procedure failed due to lower nucleophilicity of the NH₂ group in the aniline. In this case, the condensation was accomplished via acid chloride treatment of 9. In a manner similar to that of route A, the other compounds (12g-j and 13b-f), in which the a-c portions were linked with amide bonds, were prepared through route B starting from 6^{13} (P = Boc, or Z, R = H, portion b). In addition, we synthesized the compounds without the amide oxygen atom between portions b and c as shown in Scheme 2. Commercially available *N*-Boc-*L*-prolinal (14) was subjected to reductive amination utilizing NaBH₃CN with each amine, followed by deprotection of the Boc group, condensation with 5, and saponification to give the amide bond reduced analogues 13g and 13h.

Compounds were evaluated for their VLA-4 inhibitory activity in a receptor binding assay in which CHO cells expressing VLA-4 and an europium (Eu)-labeled human VCAM-1/Fc chimera were used.¹⁴ The evaluation results are summarized in Table 1.

To examine the optimal atom length (distance) between the pyrrolidine nitrogen and the carboxylic acid group in 4, we prepared proline analogues with a linear chain linker of 5–9 bonds (12a-d, Table 1). The optimal chain distance was found to be 8 bonds, as in 4, and the other chain distances resulted in a significant loss of inhibitory activity. Interestingly, the optimal distance was two bonds longer than those of the comparable positions in **Bio-1211** (1) [6 bonds (11 bonds counted from proline terminal carboxylic acid group)] and IVL-745 (2) (6 bonds) of Figure 3.

A further increase of potency was achieved by introducing a benzene ring (12f, $IC_{50} = 3.8 \text{ nM}$) or piperidine ring (13b, $IC_{50} = 2.9 \text{ nM}$) into this linker, while a similar piperazine analogue 13c retaining the same distance showed about a 2-fold decrease of potency ($IC_{50} = 13 \text{ nM}$) compared with 4 (Table 1). As for transforming the pyrrolidine ring of 4 into other hetero-rings, thiazoline analogue 12h was slightly less potent ($IC_{50} = 10 nM$) than 4, and the others (3,4-dehydropyrrolidine, piperidine, and morpholine analogues) showed a 3-4-fold decrease of potency (Table 1). Replacement of the linear linker of morpholine analogue 13d with a piperidine ring linker improved the potency again with an IC₅₀ value of 4.4nM (Table 1), suggesting that the piperidine ring could restrict the compound to the preferable conformation in this portion. Then, to further increase potency a methoxy group was introduced at the 3-position on the inner benzene ring of 4-phenylureidophenylacetic acid (portion **a**) based on the SAR previously reported by Biogen.⁶ In this case, even a combination of the 3,4dehydropyrrolidine ring and piperazine linker (13f)



Scheme 1. Reagents and conditions: (a) EDC·HCl, HOBt, Et_3N , DMF; (b) TFA, CH_2Cl_2 or H_2 , Pd/C, EtOH; (c) EDC·HCl, HOBt, Et_3N , cat. DMAP, DMF; (d) 1N NaOH, THF/MeOH.



Scheme 2. Reagents and conditions: (a) ethyl 4-piperazinylacetate, NaBH₃CN, MeOH–AcOH; (b) TFA, CH₂Cl₂; (c) EDC·HCl, HOBt, DMAP, DMF; (d) 0.25N NaOH, THF–MeOH.

showed high potency with an IC_{50} value of 1.4nM, as well as did a combination of pyrrolidine ring and piperazine linker (13e, $IC_{50} = 1.6$ nM, Table 1). For the purpose of moving away from the peptidic character by reducing H-bond acceptor, compounds were prepared by removing the amide oxygen atom between the **b** and **c** portions. Piperazinylacetic acid analogues 13g and 13h revealed equipotency to the corresponding compound amide-type 13c and 13e, revealing that this oxygen atom was unnecessary for retaining the potency.

As for 13b, 13d, and 13h with low nanomolar IC₅₀ values, we evaluated these compounds in the *Ascaris*-antigen sensitized murine airway inflammation model¹⁵ by

oral administration. Compound **13d** was found to inhibit eosinophils infiltration into bronchial alveolar lavage (BAL) fluid by 36% (50%; total cell count) at a dosage of 30 mg/kg twice a daily for 2 days compared with the vehicle alone (Fig. 4). However, the others did not show effectiveness (**13b**, 30 mg/kg b.i.d.; **13h**, 50 mg/kg b.i.d., data not shown).

On the other hand, pharmacokinetic properties in rats and physicochemical properties of 4, 13b, and 13d were determined (Table 2). Unfortunately, these compounds showed terribly low oral availability. We considered that because of rapid plasma clearance and poor membrane permeability due to lack of lipophilicity, these compounds showed poor availability. Consequently, the

Table 1. Inhibition of VLA-4/VCAM-1 by VLA-4 antagonists

	Me	N N R1 4 and 12a-j	H N Y-CO ₂ H	Me H H R1 13a-h	Z-(CH ₂)n-	CO ₂ H	
Compd	R_1	W	Х	Y	Ζ	п	IC ₅₀ (nM)
Bio-1211		_	_	_	_	_	< 0.5
4	Н	-(CH ₂) ₂ -	C=O	-(CH ₂) ₄ -	_		7.1
12a	Н	-(CH ₂) ₂ -	C=O	CH2			>1000
12b	Н	-(CH ₂) ₂ -	C=O	-(CH ₂) ₂ -			82
12c	Н	-(CH ₂) ₂ -	C=O	-(CH ₂) ₃ -			76
12d	Н	-(CH ₂) ₂ -	C=O	-(CH ₂) ₅ -			295
12e	Н	-(CH ₂) ₂ -	C=O	-CH2-trans-1,4-cyclohexyl-			121
12f	Н	-(CH ₂) ₂ -	C=O	-Ph (4-yl)-			3.8
12g	Н	-CH=CH-	C=O	-(CH ₂) ₄ -			20
12h	Н	$-S-CH_2-$	C=O	-(CH ₂) ₄ -			10
12i	Н	-(CH ₂) ₃ -	C=O	-(CH ₂) ₄ -			32
12j	Н	CH2OCH2	C=O	-(CH ₂) ₄ -			26
13a	Н	-(CH ₂) ₂ -	C=O		С	0	148
13b	Н	$-(CH_2)_2-$	C=O	_	С	1	2.9
13c	Н	-(CH ₂) ₂ -	C=O		Ν	1	13
13d	Н	CH2OCH2	C=O	_	С	1	4.4
13e	MeO	-(CH ₂) ₂ -	C=O		Ν	1	1.6
13f	MeO	-CH=CH-	C=O	_	Ν	1	1.4
13g	Н	-(CH ₂) ₂ -	$-CH_2-$	_	Ν	1	14
13h	MeO	-(CH ₂) ₂ -	$-CH_2-$	_	Ν	1	1.6



Figure 3. Comparison of optimal bond distance.



Figure 4. Effect of VLA-4/VCAM-1 antagonist on the leukocyte infiltration in BAL fluid 48 h after allergen challenge in *Ascaris suum* sensitized mice at an oral dosage 30 mg/kg twice a daily for 2 days. *p < 0.05, **p < 0.05 versus control (Student's *t*). Total numbers of cells in BAL fluid were counted, separately. Eosinophils numbers were expressed as the mean from each treatment group.

structural modification described above did not lead to significant improvement of pharmacokinetic profile.

Starting from lead compound 4, we had made modifications of the portions \mathbf{b} and \mathbf{c} corresponding to the LDV

Table 2. Pharmacokinetic and physicochemical properties of selected

 VLA-4 antagonists

Compd	F ^{a,b} (%)	Cl (i.v.) (mL/min/kg)	$t_{1/2} \lambda 1$ (min)	$t_{1/2} \lambda 2$ (min)	AT ratio ^c	$\log D^{\mathrm{d}}$
4	<1	75.1	2.8	9.1	0.6	-0.9
13b	<1	41.3	5.8	20.2	0.6	-0.3
13d	<1	69.3	6.8	42.2	0.6	-0.7

^a Male Sprague–Dawley rats.

^b Dose: i.v. infusion (2h) at 1.2mg/kg; p.o. at 5mg/kg.

^c The value of AT ratio means the ratio of Papp (test compound) to Papp (Atenolol) in Caco-2 cell permeability assay. Atenolol has been reported to show oral bioavailability of 50% in human.¹⁶

^d 1-Octanol to the Japanese Pharmacopoeia second fluid (pH6.8) partition coefficient.

sequence interacting with VLA-4 to explore the SAR. In particular, the atom length (distance) between the nitrogen atom in portion **b** and the carboxylic acid group was found to be important for the inhibitory potency (the optimal distance is 8 bonds). Furthermore, as a useful result for moving away from the peptidic character by reducing H-bond acceptor, we found that the amide bond between portions **b** and **c** is replaceable. This optimization study has led to the identification of a novel

series of 4-piperidinylacetic acid, 1-piperazinylacetic acid, and 4-aminobenzoic acid derivatives as potent VLA-4 antagonists with IC_{50} values of less than 10nM. In addition, a representative compound morpholinyl-4-piperidinylacetic acid derivative **13d** demonstrated efficacy in vivo asthma model by oral administration. Further pharmacokinetic improvements and structural modifications of these leading compounds will be presented in forthcoming publications.

References and notes

- 1. Hynes, R. O. Cell 1987, 48, 549.
- Elices, M. J.; Osborn, L.; Takeda, Y.; Crouse, C.; Luhowskyj, S.; Hemler, M. E.; Lobb, R. R. Cell 1990, 60, 577.
- (a) Guan, J. L.; Hyens, R. O. *Cell* **1990**, *60*, *53*; (b) Wayner, E. A.; Garcia-Pardo, A.; Humphries, M. J.; McDonald, J. A.; Carter, W. G. J. *Cell. Biol.* **1989**, *109*, 1321.
- Cunningham, S. A.; Rodriguez, J. M.; Arrate, M. P.; Tran, T. M.; Brock, T. A. J. Biol. Chem. 2002, 277, 27589.
- (a) Vanderslice, P.; Bidiger, R. J.; Woodside, D. G.; Berens, K. L.; Holland, G. W.; Dixon, R. A. Pulmonary Pharmacol. Therapeut. 2004, 17, 1; (b) Yang, G. I.; Hagmann, W. H. Med. Res. Rev. 2003, 23, 369; (c) Tilley, J. W. Expert Opin. Ther. Patents 2002, 12, 991; (d) Jackson, D. Y. Curr. Pharmaceut. Design 2002, 8, 1229; (e) Yusuf-Makagiansar, H.; Anderson, M. E.; Yakovleva, T. V.; Murray, J. S.; Siahaan, T. J. Med. Res. Rev. 2002, 22, 146; (f) Holland, G. W.; Biediger, R. J.; Vanderslice, P.; Annual Report in Medicinal Chemistry; Doherty, A. M., Ed.; Academic: New York, 2002; Vol. 37, p 65; (g) Porter, J. R. IDrugs 2000, 3, 788.
- Lin, K.; Ateenq, H. S.; Hsiunig, S. H.; Chong, L. T.; Zimmerman, C. N.; Castro, A.; Lee, W. C.; Hammond, C. E.; Kalkunte, S.; Chen, L. L.; Pepinsky, R. B.; Leone, D. R.; Sprague, A. G.; Abraham, W. M.; Gill, A.; Lobb, R. R.; Adams, S. P. J. Med. Chem. 1999, 42, 920.
- (a) Yednock, T. A.; Cannon, C.; Fritz, L. C.; Sanchez-Madrid, F.; Steinman, L.; Karin, N. *Nature* 1992, *356*, 63;
 (b) Piraino, P. S.; Yednock, T. A.; Freedman, S. B.; Messersmith, E. K.; Pleiss, M. A.; Vandevert, C.; Thorsett, E. D.; Karlik, S. J. J. Neuroimmunol. 2002, *131*, 147.
- 8. Seiffge, D. J. Rheumatol. 1996, 23, 2086.
- (a) Podolsky, D. K. N. Engl. J. Med. 1991, 325, 928; (b) Powrie, F.; Leach, M. W. Ther. Immunol. 1995, 2, 115.
- (a) Miller, D. H.; Khan, O. A.; Sheremata, W. A.; Blumhardt, L. D.; Rice, G. P.; Libonati, M. A.; Willmer-Hulme, A. J.; Dalton, C. M.; Miszkiel, K. A.; O'Connor, P. W. N. Engl. J. Med. 2003, 348, 15; (b) Ghosh, S.; Goldin, E.; Gordon, F. H.; Malchow, H. A.; Madsen, J. R.; Rutgeerts, P.; Vynálek, P.; Zádorová, Z.; Palmer, T.; Donoghue, S. N. Engl. J. Med. 2003, 348, 24.
- 11. Bolger, G. T. Curr. Opin. Anti-inflammat. Immunodulat. Investigat. Drugs 2002, 2, 108.
- 12. See Ref. 5a.
- (S)-Morpholinic acid derivative (6; P = Z, see Scheme 1) was synthesized as reported by: Kogami, Y.; Okawa, K. Bull. Chem. Soc. Jpn. 1987, 60, 2963.
- 14. A human VLA-4-expressing cell line, 4B4, was established at Pharmacopeia (New Jersey, USA). The 4B4 cell line was established by transfecting both the α 4 gene and β 1 gene of VLA-4 into CHO-K1 cells and maintained in F-12

medium (Ham's F-12) supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2mM L-glutamine (Invitrogen Corporation, Carlsbad, USA) and 1mg/mL G-418 (Geneticin, Invitrogen Corporation, Carlsbad, USA). Human VCAM-1/Fc Chimera (R&D Systems Inc., Minneapolis, USA) was labeled with Eu as follows. The protein was reconstituted in labeling buffer (150mM NaCl, 50mM sodium carbonate, pH8.5). Eu-Labeling Reagent (Perkin-Elmer Inc., Wellesley, USA) reconstituted with the labeling buffer was added to the protein solution. The mixture was then incubated at room temperature for 4 days. The Eu-labeled protein was purified with a PD-10 column (Amersham Biosciences KK, Tokyo, Japan) and stored at -80°C until use. All assays were performed in duplicate. Prior to the assay, 4B4 cells were suspended at 3×10^5 cells/mL in F-12 medium (Ham's F-12) supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 2mM L-glutamine (Invitrogen Corporation, Carlsbad, USA). One hundred microliters of the 4B4 cell suspension at 3×10^{5} cells/mL was distributed into each well of 96 wellculture plates (Costar, 3599, USA). The plates were incubated in a 5% CO₂ humidified incubator at 37°C (Themo Forma, model: 3120, Forma Scientific, Inc. USA) for 2 days. The medium was discarded and each well was washed twice with 300 µL of chilled Wash Buffer (25 mM HEPES (pH7.5), 150mM NaCl, 1mM CaCl₂, 1mM MgCl₂, 4mM MnCl₂). Then 50 µL of compound solution was distributed to the wells, followed by 50 µL of 2 nM of Eu-labeled Human VCAM-1/Fc Chimera diluted with the Wash Buffer (final concentration: 1nM). The plates were incubated for 60min at room temperature, and the wells were washed four times with 300 µL of chilled Wash Buffer. Finally 100 µL of the enhancement solution (Perkin-Elmer Inc., Wellesley, USA) was added to each well. The plates were placed on a shaker for 5min. Eu fluorescence was then measured in a time-resolved fluorometer (DELFIA Research fluorometer, model: 1234-001, Perkin-Elmer Inc., Wellesley, USA). The concentration of compound required for 50% inhibition in the assay was determined.

- 15. Female mice received cyclophosphamide dissolved in water administered orally at a dose of 150 mg/10 mL/kg (day 0). An extract of 500 µg of Ascaris suum protein as antigen in 0.2mL saline containing 4.5mg aluminum hydroxide as adjuvant were prepared. On day 2, 0.2 mL of the antigen solution was injected intraperitoneally. On day 14, a booster dose of the same antigen solution was injected intraperitoneally. Finally on day 22, mice were anesthetized by intraperitoneal injection with 65 mg/ 10mL/kg of pentobarbital sodium solution. After 10min, mice were challenged intratracheally with 300 µg protein of the Ascaris suum extract. The test compound was given to the mice at 15 min before and 8, 24, and 32 h after the antigen challenge. Forty-eight hours later, the lungs of mice were lavaged via a tracheal polyethylene cannula (outside diameter 1.33mm, Hibiki No. 4, Hibiki Co., Tokyo, Japan) with 2×0.5 mL Hank's balanced buffered salt solution supplemented with 0.05 mM potassium EDTA. The bronchial alveolar lavage (BAL) was performed, and the total numbers of cells in BAL fluid were counted, separately. Eosinophils numbers were expressed as the mean from each treatment group.
- (a) Artursson, P. J. Pharm. Sci. 1990, 79, 476; (b) Artursson, P.; Karlsson, J. Biochem. Biophys. Res. Commun. 1991, 175, 880.